Cytarabine Related Clinical Trials
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) [Active, not recruiting]
Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients [Completed]
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML [Active, not recruiting]
Lomustine and Intermediate Dose Cytarabine in Older Patients With AML [Completed]
DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor [Completed]
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL [Active, not recruiting]
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Active, not recruiting]
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With AML and High-Risk MDS. [Completed]
A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL) [Completed]
Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) [Completed]
High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) [Completed]
Amonafide in Combination With Cytarabine in Secondary AML [Completed]
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS [Active, not recruiting]
Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Active, not recruiting]
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Completed]
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia [Suspended]
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia [Active, not recruiting]
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia [Active, not recruiting]
High-Dose Cytarabine Plus Deoxycytidine in Treating Patients With Acute Myelogenous Leukemia or Other Hematologic Malignancies
Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients [Terminated]
3-AP and Cytarabine in Treating Patients With Hematologic Cancer [Active, not recruiting]
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia [Active, not recruiting]
Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [Active, not recruiting]
Arsenic Trioxide in Combination With Cytarabine in Patients With High-Risk MDS and Poor-Prognosis AML [Completed]
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome [Completed]
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML [Completed]
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia [Active, not recruiting]
Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Active, not recruiting]
Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma [Recruiting]
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies [No longer recruiting]
Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [Active, not recruiting]
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia [Completed]
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia [Active, not recruiting]
Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia [Completed]
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes [Completed]
Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt [Active, not recruiting]
Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia [Active, not recruiting]
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies [No longer recruiting]
Phase 3 Randomized Study of Amonafide and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary AML [Recruiting]
Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide, Compared With Low-Dose Cytarabine Alone, for the Treatment of Elderly Patients With Acute Myeloid Leukemia [Recruiting]
Phase 3 Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML) [Recruiting]
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias [Recruiting]
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline AML and High-Risk MDS [Recruiting]
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) [Recruiting]
Safety and Tolerability Study of SNS-595 and Cytarabine Combination in Acute Myeloid Leukemia in Humans [Recruiting]
Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients With High-Risk MDS and AML [Recruiting]
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) [Recruiting]
Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase [No longer recruiting]
A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer [Recruiting]
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia [No longer recruiting]
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome [Active, not recruiting]
DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis [Recruiting]
Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma [Active, not recruiting]
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse [Active, not recruiting]
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML [Recruiting]
Clofarabine Combinations in Relapsed/Refractory AML, MDS and Myeloid Blast Phase CML [Recruiting]
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory AML or High Risk MDS [Recruiting]
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes [Recruiting]
Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors [No longer recruiting]
Sorafenib and Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Recruiting]
Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML [Recruiting]
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia [Recruiting]
Clofarabine and AraC for the Treatment of AML, MDS [Active, not recruiting]
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia [Recruiting]
AMD3100 With Mitoxantrone, Etoposide and Cytarabine in Relapsed or Refractory AML [Recruiting]
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders [Recruiting]
Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia [Active, not recruiting]
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Recruiting]
Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia [No longer recruiting]
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia [Completed]
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia [Not yet recruiting]
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia [Active, not recruiting]
Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma [Completed]
PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia [Active, not recruiting]
A Non-Myeloablative Conditioning Regimen for Allogeneic Transplantation With Clofarabine, Cytarabine, and Thymoglobulin for Myelodysplastic Syndrome and Acute Myeloid Leukemia [Recruiting]
Rituximab-HCVAD in Patients With B-Cell Non-Hodgkin's Lymphoma [Recruiting]
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia [Recruiting]
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [Not yet recruiting]
Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis [Recruiting]
Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma [Recruiting]
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Recruiting]
Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes [Active, not recruiting]
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine [Recruiting]
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C [No longer recruiting]
Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine [Recruiting]
Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia [Active, not recruiting]
Daunorubicin and Cytarabine With or Without Zosuquidar Trihydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia [Active, not recruiting]
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) [Recruiting]
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Recruiting]
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia [Recruiting]
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia [Recruiting]
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia [Active, not recruiting]
Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder [Not yet recruiting]
High-Dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML [Recruiting]
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia [Recruiting]
17-N-Allylamino-17-Demethoxygeldanamycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes [Recruiting]
Azacytidine With Valproic Acid Versus Ara-C in AML/MDS Patients [Active, not recruiting]
Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia [Recruiting]
Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma [Recruiting]
|
